Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, has regained compliance with Nasdaq's bid price requirement for continued listing on the Nasdaq Capital Market. The company received notice from Nasdaq on October 16, 2024, confirming its compliance with Listing Rule 5550(a)(2).
As a result, Sonnet will be subject to a Mandatory Panel Monitor for one year from October 16, 2024. If the company falls out of compliance with the Bid Price Rule during this period, it will face stricter consequences, including potential delisting without the opportunity to provide a compliance plan or receive additional time to regain compliance.
- Regained compliance with Nasdaq's bid price requirement
- Continued listing on the Nasdaq Capital Market
- Subject to Mandatory Panel Monitor for one year
- Risk of potential delisting if bid price compliance is lost again within the monitoring period
Insights
Sonnet BioTherapeutics' regaining compliance with Nasdaq's bid price requirement is a positive development for the company's market status. This outcome averts the immediate risk of delisting, which could have severely impacted investor confidence and the company's ability to raise capital.
However, the implementation of a Mandatory Panel Monitor for one year introduces a heightened level of scrutiny. This monitoring period creates a precarious situation for Sonnet, as any future non-compliance with the bid price rule could result in a swift delisting process without the usual remediation opportunities.
For investors, this news represents a double-edged sword. While the immediate threat is resolved, the company now operates under stricter conditions. The lack of a compliance plan option or cure period in case of future violations significantly increases the risk profile for Sonnet's continued Nasdaq listing.
Shareholders should closely monitor the stock's performance, as maintaining compliance will be important for Sonnet's market accessibility and overall valuation. This situation underscores the importance of sustainable share price improvement for the company's long-term stability on Nasdaq.
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it received notice on October 16, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company regained compliance with the bid price requirement in Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing on the Nasdaq Capital Market.
Accordingly, in application of Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from October 16, 2024. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (“Staff”) finds the Company again out of compliance with the Bid Price Rule that was the subject of the exception, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company’s securities may be at that time delisted from Nasdaq.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.
Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Material Supply Agreement with Roche in combination with atezolizumab (Tecentriq®) for the treatment of Platinum-Resistant Ovarian Cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of Pancreatic Cancer.
The Company’s SON-080 program is a low dose of rhIL-6 in development for CIPN and DPN. SON-080 demonstrated encouraging results in a Phase 1b/2a clinical trial, being well tolerated with no evidence of a pro-inflammatory cytokine response. Sonnet is currently seeking partnership opportunities to support a Phase 2 trial.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s ability to maintain compliance with the rules for continued listing on the Nasdaq Capital Market, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
SONN@jtcir.com
FAQ
What did Sonnet BioTherapeutics (SONN) announce on October 17, 2024?
How long will Sonnet BioTherapeutics (SONN) be under Mandatory Panel Monitor?
What happens if Sonnet BioTherapeutics (SONN) falls out of compliance again during the monitoring period?
